North America (United States, Canada and Mexico)Įurope (Germany, France, UK, Russia and Italy)Īsia-Pacific (China, Japan, Korea, India and Southeast Asia) Market Segment by Applications, can be divided into: In terms of revenue, the global top four players hold a share over % in 2021.įor More Information On This Report, Please Visit Segment by Manufacturers, this report covers :

Hoffmann-La Roche, Medline Industries, Meridian Bioscience, and Bio-Rad Laboratories, etc. Global key companies of Non-invasive Helicobacter Pylori Diagnostic include Sekisui Diagnostics, F. While Invasive Techniques segment is altered to a % CAGR between 20. Hospitals and Clinics accounting for % of the Non-invasive Helicobacter Pylori Diagnostic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. Since the introduction of rapid molecular tests and the 2018 FDA Flu reclassification focusing on the improved performance of on market rapid immunoassays, clinicians are now more confident in test results and therefore better able to provide direct therapy.The Non-invasive Helicobacter Pylori Diagnostic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.Īccording to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-invasive Helicobacter Pylori Diagnostic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Testing patients provides valuable information to the clinician that can enable them to rule out other illnesses, help determine treatment and reduces the risk of prescribing unnecessary antivirals or antibiotics. 'Accurate diagnosis of influenza is critical to minimize transmission of infection and we are proud to be able to provide sensitive and specific tools to healthcare professionals.' We remain committed to providing innovative, high quality testing options so they can make the right choice for their practices and patients,' said Robert Schruender, president /CEO of Sekisui Diagnostics. We take great pride in listening to our customers and we understand they have different needs during flu season. The launch of the Acucy Influenza A&B Test makes us the first and only company to provide the three most commonly used flu testing methods in a CLIA Waived format. 'This is a very exciting time for Sekisui Diagnostics. Sekisui Diagnostics now offers options to address the varying needs of the market to help improve patient outcomes, maximize clinical efficiencies, and reduce operational budgets. The addition of the Acucy Influenza A&B test expands Sekisui Diagnostics flu portfolio to include all three commonly used modalities in the CLIA Waived environment: OSOM Ultra Flu A&B Test (manual read lateral flow), Acucy Influenza A&B Test (point-of-care reader) and the Silaris Influenza A&B Test (molecular point-of-care). Utilizing the Acucy Reader in either the point-of-care or laboratory setting provides workflow flexibility with Read Now and Walk Away features. The combination of the Influenza A&B Test and the Reader provides clinicians with standardized and definitive result interpretation. The Acucy Influenza A&B Test is intended for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. Food and Drug Administration (FDA), as well as, CLIA Waiver (Clinical Laboratory Improvement Amendments) for use on the Acucy Reader. Sekisui Diagnostics’ Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the U.S.

Sekisui diagnostics